Department of Safety and Bioethics, Infectious Diseases Institute, Catholic University of Sacred Heart, Rome, Italy.
UOC Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
AIDS Patient Care STDS. 2022 May;36(5):178-185. doi: 10.1089/apc.2022.0030.
Two hundred two people living with HIV (PLWH) selected from outpatients at the Infectious Disease Institute, Fondazione Policlinico Universitario A. Gemelli IRCCS, in Rome (Italy) were consecutively enrolled from May to July 2021. We used an anonymous telephone questionnaire to investigate opinions of PLWH about combined antiretroviral (ARV) therapy and long-acting (LA) formulations of ARVs. All invited participants completed the questionnaire (100%). We found that most PLWH evaluated taking HIV pills for the rest of their life as a continuous, but undemanding commitment (61.4%; = 124), although they were willing to stop the daily intake of HIV drugs (78.2%, = 158). Moreover, most PLWH were unaware of the existence of LA therapies at the time of the investigation (60.4%, = 122). Almost half the PLWH evaluated the need for injections in the hospital as an obstacle (51.4%, = 104). Regarding the preference between monthly injections and taking pills everyday, most PLWH (68.8%, = 139) stated that the injection was more advantageous than pills even if they had some pain/swelling at the injection site. The concern about LA therapy indicated most by PLWH was the possible lower efficacy of the drug (83.7%, = 169). Regarding the possible benefits of LA therapy, those reported most by PLWH were feeling freer because they did not have to remember to take pills everyday (68,8%, = 139). In conclusion, to date, PLWH in our cohort seem willing to accept LA therapy, but still show some concern about the efficacy of the new therapy and the obligation to come to the hospital to receive it. Thus, clinicians must take into account the needs of their patients and help them overcome their concerns to facilitate the transition to this new therapeutic modality. Clinical Trial Registration Number ID: 2424.
2021 年 5 月至 7 月，我们连续从罗马（意大利）传染病研究所 Fondazione Policlinico Universitario A. Gemelli IRCCS 的门诊患者中招募了 202 名 HIV 感染者（PLWH）。我们使用匿名电话问卷调查了 PLWH 对联合抗逆转录病毒（ARV）治疗和长效（LA）ARV 制剂的看法。所有受邀参与者都完成了问卷（100%）。我们发现，大多数 PLWH 将终生服用 HIV 药物视为一项持续但无需费力的承诺（61.4%，124 人），尽管他们愿意停止每日服用 HIV 药物（78.2%，158 人）。此外，大多数 PLWH 在调查时不知道存在 LA 治疗（60.4%，122 人）。近一半的 PLWH 将需要在医院注射视为障碍（51.4%，104 人）。关于每月注射和每天服药的偏好，大多数 PLWH（68.8%，139 人）表示，即使注射部位有一些疼痛/肿胀，注射也比服药更有利。PLWH 最关心的 LA 治疗问题是药物可能的疗效降低（83.7%，169 人）。关于 LA 治疗的可能益处，PLWH 报告最多的是感觉更自由，因为他们不必每天记得服药（68.8%，139 人）。总之，迄今为止，我们队列中的 PLWH 似乎愿意接受 LA 治疗，但仍对新疗法的疗效和到医院接受治疗的义务表示一些担忧。因此，临床医生必须考虑患者的需求，并帮助他们克服这些担忧，以促进向这种新治疗模式的转变。临床试验注册号：2424。
